apg-1252 + paclitaxel

**APG-1252 + paclitaxel** is a combination therapy consisting of the investigational agent APG-1252 (also known as pelcitoclax), a dual BCL-2/BCL-xL inhibitor, and paclitaxel, a microtubule-stabilizing chemotherapeutic[3][7][1]. APG-1252 is a small molecule, orally bioavailable BH3 mimetic that binds to BCL-2 and BCL-xL, disrupting their anti-apoptotic activity and promoting apoptosis in cancer cells[2][6][3][7]. This mechanism is particularly relevant in tumors with high expression of BCL-2 family proteins, like small cell lung cancer (SCLC). Paclitaxel complements APG-1252 by inhibiting cell division via stabilization of microtubules, leading to cell cycle arrest and apoptosis. The combination is studied in adults with relapsed/refractory small cell lung cancer (R/R SCLC), particularly those who have failed initial platinum-based therapies, owing to its potential synergistic antitumor activity[3][7][1]. The regimen is designed to augment apoptotic signaling, overcome tumor survival mechanisms, and enhance clinical efficacy beyond standard chemotherapeutics alone. APG-1252 is being developed by Ascentage Pharma.

Brand names

pelcitoclax

Other names

APG-1252 + paclitaxelpelcitoclax + paclitaxel